Tag: CVRx
Barostim neuromodulation device misses primary endpoint in BEAT-HF trial
CVRx has announced the preliminary topline results of the BEAT-HF (Baroreflex activation therapy for heart failure) postmarket clinical trial.
The BEAT-HF postmarket phase of the...
CVRx launches new version of neuromodulation device intended to treat heart...
CVRx—the developer of the “world’s first” US Food and Drug Administration (FDA)-approved neuromodulation device to treat the symptoms of heart failure—has launched its new...
